Actively Recruiting
Evaluating Oral ENV-294 for Adults With Moderate-to-Severe Asthma Under Standard Inhaled Treatment Over 12 Weeks
Led by Enveda Therapeutics · Updated on 2026-09-24
50
Participants Needed
20
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and potential effectiveness of an investigational drug called ENV-294 in adults with moderate to severe asthma. Participants in this study are already receiving background treatment with inhaled corticosteroids ICS and long-acting beta2-agonists LABA. The study aims to better understand how ENV-294 works and its impact on asthma control. Participants will be randomly assigned to receive either oral ENV-294 or a placebo once daily for 12 weeks. Before starting treatment, there is a screening period of up to 28 days to confirm eligibility. The study includes two groups one receiving ENV-294 tablets daily and the other receiving matching placebo tablets under the same conditions. Throughout the study, participants will attend visits for assessments to monitor safety, measure drug levels in the blood, and evaluate lung function and asthma control. The main outcome measured is the incidence and severity of adverse events from the first dose through about 16 weeks. Other evaluations include loss of asthma control events, time to loss of asthma control, and plasma concentrations of ENV-294. The total participation time includes screening and 12 weeks of treatment.
CONDITIONS
Brief Title
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
Research Team
C
Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here